Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, AstraZeneca Will Consider Developing New Cell-based Microfluidic Screening Tool

NEW YORK, May 3 (GenomeWeb News) - Cellectricon and AstraZeneca will "study the possibility" of developing a new cell-based microfluidic screening platform, Cellectricon said today.

 

The collaboration specifically aims to improve cell-based ion-channel assays in screening applications, Cellectricon said.

 

Financial terms of the alliance were not disclosed.

 

This isn't the first time the companies have crossed paths. Last June, AstraZeneca installed several of Cellectricon's DynaFlow ion channels screening platforms worldwide.

 

Cell-Based Assay News, a GenomeWeb News sister publication, reported in June 2004 that AstraZeneca had decided to use DynaFlow in its ion channel drug-discovery program. Cellectricon said today that AstraZeneca has placed multiple orders for DynaFlow systems since that time.

 

DynaFlow is based on a computer-controlled microfluidic chip, and is designed to be used with any cell, patch-clamp configuration, active substance, and ion channel, Cellectricon said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.